File
Title Alternative
Resolvin E1は骨芽細胞におけるIL-17誘導性RANKL発現とRANKL誘導性破骨細胞分化を抑制することで破骨細胞形成および骨吸収を抑制する
Authors
Keywords
interleukin-17
osteoblasts
osteoclasts
RANK ligand
resolvin E1
Abstract
【Background】 Resolvin E1 (RvE1) derived from the ω-3 polyunsaturated fatty acid eicosapentaenoic acid is known to be a potent pro-resolving lipid mediator that prevents chronic inflammation and osteoclastogenesis. We investigated the inhibitory effects of RvE1 on osteoclastogenesis and bone resorption to clarify its therapeutic potential for rheumatoid arthritis (RA).
【Methods】 Receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation was assessed with tartrate-resistant acid phosphatase staining. RANKL-induced bone resorption was assessed by the measurement of pit formation using calcium phosphate-labeled fluorescent polyanionic molecules in RAW264.7 cells as osteoclast precursors. The effects of RvE1 on the RANKL-induced mRNA expression of osteoclast-specific genes and transcriptional factors such as c-fos and nuclear factor of activated T cells c1 (NFATc1) in RAW264.7 cells were measured by quantitative real-time PCR. The distribution of NFATc1 induced by RANKL was evaluated by immunofluorescence staining in RAW264.7 cells. To analyze the mechanism of the inhibitory effect of RvE1 on osteoclastogenesis, we measured IL-17-induced RANKL mRNA expression in MC3T3-E1 osteoblast cells treated with RvE1 using quantitative real-time PCR and determined the level of prostaglandin E2 (PGE2) production by enzyme-linked immunosorbent assay.
【Results】 RvE1 significantly suppressed RANKL-induced osteoclast differentiation and bone resorption. RvE1 inhibited the RANKL-induced mRNA expression of osteoclast-specific genes along with the transcription factors NFATc1 and c-fos. Moreover, NFATc1 translocation from the cytoplasm to the nucleus of RAW264.7 cells was suppressed following RvE1 treatment. RvE1 also inhibited IL-17-induced RANKL mRNA expression and PGE2 production in MC3T3-E1 cells.
【Conclusion】 RvE1 inhibited osteoclastogenesis and bone resorption by suppressing RANKL-induced NFATc1 and c-fos expression in osteoclasts and IL-17- induced RANKL expression through the autocrine action of PGE2 in osteoblasts. Our data suggest RvE1 as a new therapeutic target of RA.
Content Type
Thesis or Dissertation
Link
Current Journal Title
Published Date
2018-03-01
Text Version
ETD
Rights
注があるものを除き、この著作物は日本国著作権法により保護されています。
Citation
This research was published by Yonago Acta Medica: Yoshihiro Funaki, Yasuyuki Hasegawa, Ryota Okazaki, Akira Yamasaki, Yuriko Sueda, Akihiro Yamamoto, Masaaki Yanai, Takehito Fukushima, Tomoya Harada, Haruhiko Makino and Eiji Shimizu. Resolvin E1 Inhibits Osteoclastogenesis and Bone Resorption by Suppressing IL-17-induced RANKL Expression in Osteoblasts and RANKL-induced Osteoclast Differentiation. Yonago Acta Medica, 2018, 61, pp.8-18
Language
English
Grant ID
甲第880号
Granted Date
2018-03-01
Degree Name
博士(医学)
Grantor
鳥取大学